- See Also
-
Links
- “Efficacy and Safety of Tirzepatide Monotherapy Compared With Dulaglutide in Japanese Patients With Type 2 Diabetes (SURPASS J-mono): a Double-blind, Multicentre, Randomised, Phase 3 Trial”, Et Al 2022
- “Tirzepatide Once Weekly for the Treatment of Obesity”, Et Al 2022
- “FDA Approves Lilly’s Mounjaro™ (tirzepatide) Injection, the First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Adults With Type 2 Diabetes”, 2022
- “Lilly’s Tirzepatide Delivered up to 22.5% Weight Loss in Adults With Obesity or Overweight in SURMOUNT-1”, 2022
- “Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial”, Et Al 2022
- “Anti-obesity Drug Discovery: Advances and Challenges”, Et Al 2021
- “Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): a Randomised, Open-label, Parallel-group, Multicentre, Phase 3 Trial”, Et Al 2021
- “Once-weekly Tirzepatide versus Once-daily Insulin Degludec As Add-on to Metformin With or without SGLT2 Inhibitors in Patients With Type 2 Diabetes (SURPASS-3): a Randomised, Open-label, Parallel-group, Phase 3 Trial”, Et Al 2021
- “Tirzepatide versus Semaglutide Once Weekly in Patients With Type 2 Diabetes [SURPASS-2]”, Et Al 2021
- “Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): a Double-blind, Randomised, Phase 3 Trial”, Et Al 2021
- “Society Is Fixed, Biology Is Mutable”
- Wikipedia
- Link Bibliography
See Also
Links
“Efficacy and Safety of Tirzepatide Monotherapy Compared With Dulaglutide in Japanese Patients With Type 2 Diabetes (SURPASS J-mono): a Double-blind, Multicentre, Randomised, Phase 3 Trial”, Et Al 2022
“Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial”, 2022-07-29 (similar)
“Tirzepatide Once Weekly for the Treatment of Obesity”, Et Al 2022
“Tirzepatide Once Weekly for the Treatment of Obesity”, 2022-06-04 (similar)
“FDA Approves Lilly’s Mounjaro™ (tirzepatide) Injection, the First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Adults With Type 2 Diabetes”, 2022
“FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes”, 2022-05-13 (similar; bibliography)
“Lilly’s Tirzepatide Delivered up to 22.5% Weight Loss in Adults With Obesity or Overweight in SURMOUNT-1”, 2022
“Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1”, 2022-04-28 (backlinks; similar)
“Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial”, Et Al 2022
“Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial”, 2022-02-08 (backlinks; similar)
“Anti-obesity Drug Discovery: Advances and Challenges”, Et Al 2021
“Anti-obesity drug discovery: advances and challenges”, 2021-11-23 (; similar)
“Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4): a Randomised, Open-label, Parallel-group, Multicentre, Phase 3 Trial”, Et Al 2021
“Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial”, 2021-11-13 (backlinks; similar; bibliography)
“Once-weekly Tirzepatide versus Once-daily Insulin Degludec As Add-on to Metformin With or without SGLT2 Inhibitors in Patients With Type 2 Diabetes (SURPASS-3): a Randomised, Open-label, Parallel-group, Phase 3 Trial”, Et Al 2021
“Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial”, 2021-08-14 (backlinks; similar; bibliography)
“Tirzepatide versus Semaglutide Once Weekly in Patients With Type 2 Diabetes [SURPASS-2]”, Et Al 2021
“Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes [SURPASS-2]”, 2021-08-05 (backlinks; similar; bibliography)
“Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): a Double-blind, Randomised, Phase 3 Trial”, Et Al 2021
“Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial”, 2021-07-10 (backlinks; similar)
“Society Is Fixed, Biology Is Mutable”
Wikipedia
Link Bibliography
-
https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and: “FDA Approves Lilly's Mounjaro™ (tirzepatide) Injection, the First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Adults With Type 2 Diabetes”, Eli Lilly: -
2021-delprato.pdf: “Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (<strong>SURPASS-4< / strong>): a Randomised, Open-label, Parallel-group, Multicentre, Phase 3 Trial”, : -
2021-frias.pdf: “Tirzepatide versus Semaglutide Once Weekly in Patients With Type 2 Diabetes [<strong>SURPASS-2< / strong>]”, :